139 related articles for article (PubMed ID: 38920981)
1. Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside.
Evangelidis N; Kotsiou N; Evangelidis P; Alevizopoulos VI; Dermitzakis I; Chissan S; Vakalopoulou S; Gavriilaki E
Curr Issues Mol Biol; 2024 May; 46(6):5147-5160. PubMed ID: 38920981
[TBL] [Abstract][Full Text] [Related]
2. Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors.
Bonnefoy A; Merlen C; Dubé E; Claus-Desbonnet H; Rivard GE; St-Louis J
J Thromb Haemost; 2021 Dec; 19(12):2947-2956. PubMed ID: 34455699
[TBL] [Abstract][Full Text] [Related]
3. Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.
Sakurai Y; Takeda T
J Immunol Res; 2014; 2014():320674. PubMed ID: 24741588
[TBL] [Abstract][Full Text] [Related]
4. [Systemic lupus erythematosus with acquired hemophilia A: a case report].
Yang F; Zhou YS; Jia Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1108-1111. PubMed ID: 30562791
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Acquired Hemophilia A: Case Reports and a Literature Review.
Rinaldi I; Prasetyawaty F; Fazlines S; Winston K; Samudera Nurrobi YA; Leoni J; Restu Tulus Maha IH; Wicaksono S; Wicaksono AY; Aslani AO; Ikhsani R
Case Rep Med; 2021; 2021():5554664. PubMed ID: 34567128
[TBL] [Abstract][Full Text] [Related]
6. Review of Potential Barriers to Effective Hemostatic Management of Acquired Hemophilia A by Non-Hemophilia Experts in the United States.
Sharathkumar A; Mokdad AG
Cureus; 2023 Jan; 15(1):e33927. PubMed ID: 36819387
[TBL] [Abstract][Full Text] [Related]
7. Acquired hemophilia: a case report and review of the literature.
Mulliez SM; Vantilborgh A; Devreese KM
Int J Lab Hematol; 2014 Jun; 36(3):398-407. PubMed ID: 24750687
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?
Franchini M; Schiavulli M; Liumbruno GM
Expert Rev Hematol; 2021 Mar; 14(3):263-270. PubMed ID: 33655810
[No Abstract] [Full Text] [Related]
9. Inhibitor eradication and treatment for acquired hemophilia A.
Franchini M; Focosi D
Expert Rev Hematol; 2024 Jun; 17(6):233-240. PubMed ID: 38708599
[TBL] [Abstract][Full Text] [Related]
10. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.
Wyseure T; Cooke EJ; Declerck PJ; Behrendt N; Meijers JCM; von Drygalski A; Mosnier LO
Blood; 2018 Oct; 132(15):1593-1603. PubMed ID: 30026184
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up.
Chansavang A; Philippe A; Bozinovic I; Ben Hadj Ali K; Smadja D; Helley D; Darnige L; Mauge L
Ann Hematol; 2022 Nov; 101(11):2453-2460. PubMed ID: 36125542
[TBL] [Abstract][Full Text] [Related]
12. The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.
Lapalud P; Ali T; Cayzac C; Mathieu-Dupas E; Levesque H; Pfeiffer C; Balicchi J; Gruel Y; Borg JY; Schved JF; Granier C; Lavigne-Lissalde G
J Thromb Haemost; 2012 Sep; 10(9):1814-22. PubMed ID: 22784315
[TBL] [Abstract][Full Text] [Related]
13. Acquired Hemophilia A and urothelial carcinoma.
Taza F; Suleman N; Paz R; Haas C
J Community Hosp Intern Med Perspect; 2021 Jan; 11(1):89-93. PubMed ID: 33552425
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of Idiopathic Acquired Hemophilia Type A.
Amu-Hernández LA; Marzo-Alonso C; Tugues-Peiró A; Vicente-Pascual EP; Monteagudo-Aguilar P
Cureus; 2023 May; 15(5):e38634. PubMed ID: 37284359
[TBL] [Abstract][Full Text] [Related]
15. Acquired Hemophilia A in IgG4-Related Disease: Case Report, Immunopathogenic Study, and Review of the Literature.
Sanges S; Jeanpierre E; Lopez B; Russick J; Delignat S; Carpentier B; Dubois R; Dubucquoi S; Guerrier T; Hachulla É; Hatron PY; Paris C; Susen S; Launay D; Lacroix-Desmazes S; Terriou L
Front Immunol; 2020; 11():558811. PubMed ID: 33424828
[TBL] [Abstract][Full Text] [Related]
16. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?
Mahendra A; Padiolleau-Lefevre S; Kaveri SV; Lacroix-Desmazes S
Br J Haematol; 2012 Jan; 156(1):3-12. PubMed ID: 21988190
[TBL] [Abstract][Full Text] [Related]
17. Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur.
Miatech JL; Kantamani D; Stagg MP
Cureus; 2021 Oct; 13(10):e19145. PubMed ID: 34868780
[TBL] [Abstract][Full Text] [Related]
18. A Case of Acquired Hemophilia A and Congenital Hemophilia B.
Fortier JC; Pang SS; Amofa-Ho S; Harris NS; Zumberg M
Cureus; 2022 Oct; 14(10):e30324. PubMed ID: 36407152
[TBL] [Abstract][Full Text] [Related]
19. The tipping point: The critical role of therapeutic apheresis in a case of refractory acquired hemophilia.
Losos M; Scrape S; Joshi S; Shmookler A; Chen J
J Clin Apher; 2017 Dec; 32(6):564-566. PubMed ID: 27646211
[TBL] [Abstract][Full Text] [Related]
20. [Acquired hemophilia A with reappearance of inhibitor 10 years after the completion of immunosuppressive therapy].
Oshida K; Ito T; Shirayama R; Kusuhara K; Sato T; Sakai M
Rinsho Ketsueki; 2021; 62(3):186-189. PubMed ID: 33828012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
